Bio-Rad Laboratories (BIO)

$268.25 -3.05 (-1.12%)
Market Cap 7.32B
Revenue (ttm) 2.58B
Net Income (ttm) 759.90M
EPS (ttm) N/A
PE Ratio 27.41
Forward PE 26.25
Profit Margin 29.42%
Debt to Equity Ratio 0.16
Volume 282,100
Avg Vol 241,060
Day's Range N/A - N/A
Shares Out 26.98M
Stochastic %K 34%
Beta 1.18
Analysts Sell
Price Target $327.50

Company Profile

Bio-Rad Laboratories, Inc. manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials, such as cells, proteins, and nucleic acids used in biopharmaceutical manufacturing, q...

Industry: Medical Devices
Sector: Healthcare
Phone: 510 724 7000
Fax: 510 741 5817
Address:
1000 Alfred Nobel Drive, Hercules, United States
SuperGreenToday
SuperGreenToday Feb. 23 at 2:58 PM
$BIO Share Price: $268.70 Contract Selected: Sep 18, 2026 $270 Calls Buy Zone: $21.42 – $26.46 Target Zone: $35.96 – $43.96 Potential Upside: 59% ROI Time to Expiration: 206 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
TheDizPlinTrader
TheDizPlinTrader Feb. 20 at 1:56 PM
$BIO 🧪 1 Hour Levels Price: $272.00 Support: $264.40 Resistance: $279.90 👉 Tap follow to keep these 1-hour levels on your feed.
0 · Reply
MarketMicrostructure
MarketMicrostructure Feb. 20 at 1:18 PM
$BIO Bio-Rad supplies life science and diagnostics tools. Growth depends on research funding. Margins benefit from consumables.
0 · Reply
ZacksResearch
ZacksResearch Feb. 19 at 2:15 PM
$BIO just reminded the market that margins matter. ⚠️ Q4 EPS missed estimates, margins shrank, and shares slid 12% — even with revenue growth and a rebound in Clinical Diagnostics sales. Top-line strength wasn’t enough to offset profitability pressure. Is this a warning sign or an overreaction? Get the full picture 👉 https://www.zacks.com/stock/news/2871875/bio-rads-q4-earnings-miss-estimates-revenues-surpass-stock-down?cid=sm-stocktwits-2-2871875-teaser-34197&ADID=SYND_STOCKTWITS_TWEET_2_2871875_TEASER_34197
0 · Reply
ZacksResearch
ZacksResearch Feb. 19 at 1:15 PM
$BIO drops 12.3% after Q4 earnings miss! 📉 EPS of $2.51 fell short by 2.3%, and operating margins missed expectations, causing investor concern. ⚠️ See the full breakdown here 👉 https://www.zacks.com/stock/news/2871875/bio-rads-q4-earnings-miss-estimates-revenues-surpass-stock-down?cid=sm-stocktwits-2-2871875-body-34160&ADID=SYND_STOCKTWITS_TWEET_2_2871875_BODY_34160
0 · Reply
Bazzzigar
Bazzzigar Feb. 17 at 1:02 PM
$BIO UNH
0 · Reply
SuperGreenToday
SuperGreenToday Feb. 13 at 10:20 PM
$BIO Share Price: $256.26 Contract Selected: Sep 18, 2026 $300 Calls Buy Zone: $11.05 – $13.65 Target Zone: $19.04 – $23.28 Potential Upside: 63% ROI Time to Expiration: 216 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
StocktwitsEarnings
StocktwitsEarnings Feb. 12 at 9:24 PM
$BIO Q4 '25 Earnings Results & Recap • Reported GAAP EPS of $26.69 up 204.38% YoY • Reported revenue of $693.2M up 3.85% YoY • Bio-Rad expects non-GAAP currency neutral revenue growth of approximately 0.5% to 1.5% and an estimated non-GAAP operating margin of 12.0% to 12.5% for the full-year 2026.
0 · Reply
stock_head
stock_head Feb. 12 at 8:15 PM
$BIO someone is slamming a bunch of otm calls on this rn. Looks like they might have ER today
1 · Reply
HHill
HHill Feb. 12 at 8:06 PM
$BIO loading calls here Will rocket 🚀
0 · Reply
Latest News on BIO
Bio-Rad Laboratories, Inc. (BIO) Q4 2025 Earnings Call Transcript

Feb 12, 2026, 7:34 PM EST - 11 days ago

Bio-Rad Laboratories, Inc. (BIO) Q4 2025 Earnings Call Transcript

Bio-Rad Reports Fourth-Quarter and Full-Year 2025 Financial Results

Feb 12, 2026, 4:15 PM EST - 11 days ago

Bio-Rad Reports Fourth-Quarter and Full-Year 2025 Financial Results

Bio-Rad to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 12, 2026

Jan 29, 2026, 8:30 AM EST - 26 days ago

Bio-Rad to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 12, 2026

Artisan Mid Cap Value Fund Q4 2025 Performance Discussion And Portfolio Activity

Jan 21, 2026, 1:33 PM EST - 4 weeks ago

Artisan Mid Cap Value Fund Q4 2025 Performance Discussion And Portfolio Activity

CABO CDW CNC EXPE FCNCA LKQ NOV

Longleaf Partners Global Fund 2025 Contributors And Detractors

Jan 15, 2026, 10:00 AM EST - 5 weeks ago

Longleaf Partners Global Fund 2025 Contributors And Detractors

ANGI AVTR IAC MGM TIGO

Bio-Rad's Management to Host Investor Meetings at J.P. Morgan's 44th Annual Healthcare Conference

Jan 6, 2026, 8:45 AM EST - 7 weeks ago

Bio-Rad's Management to Host Investor Meetings at J.P. Morgan's 44th Annual Healthcare Conference

Bio-Rad Laboratories, Inc. (BIO) Q3 2025 Earnings Call Transcript

Oct 29, 2025, 7:56 PM EDT - 4 months ago

Bio-Rad Laboratories, Inc. (BIO) Q3 2025 Earnings Call Transcript

Bio-Rad Reports Third-Quarter 2025 Financial Results

Oct 29, 2025, 4:15 PM EDT - 4 months ago

Bio-Rad Reports Third-Quarter 2025 Financial Results

Compelling Value In Small-Cap Equities And Select Cyclicals

Oct 23, 2025, 11:45 PM EDT - 4 months ago

Compelling Value In Small-Cap Equities And Select Cyclicals

AJG B CLB FISV HON MOS REZI

7 Stocks Taking The Next Step To Be On Offense

Oct 23, 2025, 7:30 PM EDT - 4 months ago

7 Stocks Taking The Next Step To Be On Offense

ACI CNX FCF FDX FIS IAC KHC

It's time to scoop up undervalued stocks in this critical sector of the economy

Oct 21, 2025, 11:07 AM EDT - 4 months ago

It's time to scoop up undervalued stocks in this critical sector of the economy

BSX ISRG SYK BDX BDYN FEGE JGLO

Bio-Rad to Report Third Quarter 2025 Financial Results on Wednesday, October 29, 2025

Oct 16, 2025, 5:30 PM EDT - 4 months ago

Bio-Rad to Report Third Quarter 2025 Financial Results on Wednesday, October 29, 2025

Biorad Medisys announces its entry into the US market with the launch of its new subsidiary Medtimo Inc.

Sep 4, 2025, 5:19 PM EDT - 6 months ago

Biorad Medisys announces its entry into the US market with the launch of its new subsidiary Medtimo Inc.

Bio-Rad Laboratories, Inc. (BIO) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 (Transcript)

Sep 4, 2025, 5:07 PM EDT - 6 months ago

Bio-Rad Laboratories, Inc. (BIO) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 (Transcript)

Bio-Rad's Management to Participate in Upcoming Investor Conferences

Aug 25, 2025, 9:00 AM EDT - 6 months ago

Bio-Rad's Management to Participate in Upcoming Investor Conferences

Bio-Rad Laboratories: Macroeconomic Uncertainty And A Limited Growth Potential Give Pause

Aug 7, 2025, 7:30 AM EDT - 7 months ago

Bio-Rad Laboratories: Macroeconomic Uncertainty And A Limited Growth Potential Give Pause

Bio-Rad Laboratories Analysts Raise Their Forecasts After Better-Than-Expected Q2 Earnings

Aug 1, 2025, 11:30 AM EDT - 7 months ago

Bio-Rad Laboratories Analysts Raise Their Forecasts After Better-Than-Expected Q2 Earnings

Bio-Rad to Host Droplet Digital PCR Webinar on Tuesday, August 26, 2025

Aug 1, 2025, 9:00 AM EDT - 7 months ago

Bio-Rad to Host Droplet Digital PCR Webinar on Tuesday, August 26, 2025

Bio-Rad Laboratories, Inc. (BIO) Q2 2025 Earnings Call Transcript

Jul 31, 2025, 9:55 PM EDT - 7 months ago

Bio-Rad Laboratories, Inc. (BIO) Q2 2025 Earnings Call Transcript

Bio-Rad Reports Second-Quarter 2025 Financial Results

Jul 31, 2025, 4:15 PM EDT - 7 months ago

Bio-Rad Reports Second-Quarter 2025 Financial Results

Bio-Rad Appoints Rajat Mehta Executive Vice President, Global Commercial Operations

Jul 28, 2025, 4:15 PM EDT - 7 months ago

Bio-Rad Appoints Rajat Mehta Executive Vice President, Global Commercial Operations

Bio-Rad to Report Second Quarter 2025 Financial Results on Thursday, July 31, 2025

Jul 17, 2025, 4:15 PM EDT - 7 months ago

Bio-Rad to Report Second Quarter 2025 Financial Results on Thursday, July 31, 2025

Bio-Rad Expands Droplet Digital PCR Offering Through Strategic Acquisition and Platform Rollout

Jul 7, 2025, 9:00 AM EDT - 8 months ago

Bio-Rad Expands Droplet Digital PCR Offering Through Strategic Acquisition and Platform Rollout

Bio-Rad's Management to Host Investor Meetings During Jefferies Global Healthcare Conference

May 29, 2025, 4:30 PM EDT - 9 months ago

Bio-Rad's Management to Host Investor Meetings During Jefferies Global Healthcare Conference

Bio-Rad's Management to Participate in Fireside Chat During 2025 RBC Capital Markets Global Healthcare Conference

May 12, 2025, 4:30 PM EDT - 10 months ago

Bio-Rad's Management to Participate in Fireside Chat During 2025 RBC Capital Markets Global Healthcare Conference

Bio-Rad Laboratories, Inc. (BIO) Q1 2025 Earnings Call Transcript

May 1, 2025, 10:35 PM EDT - 10 months ago

Bio-Rad Laboratories, Inc. (BIO) Q1 2025 Earnings Call Transcript

Bio-Rad Reports First-Quarter 2025 Financial Results

May 1, 2025, 4:15 PM EDT - 10 months ago

Bio-Rad Reports First-Quarter 2025 Financial Results

Bio-Rad Laboratories, Inc. (BIO) Q4 2024 Earnings Call Transcript

Feb 13, 2025, 11:45 PM EST - 1 year ago

Bio-Rad Laboratories, Inc. (BIO) Q4 2024 Earnings Call Transcript

Bio-Rad Reports Fourth-Quarter and Full-Year 2024 Financial Results

Feb 13, 2025, 4:20 PM EST - 1 year ago

Bio-Rad Reports Fourth-Quarter and Full-Year 2024 Financial Results

Bio-Rad Offers to Acquire Digital PCR Developer Stilla Technologies

Feb 13, 2025, 4:15 PM EST - 1 year ago

Bio-Rad Offers to Acquire Digital PCR Developer Stilla Technologies

Bio-Rad to Report Fourth Quarter and Full Year 2024 Financial Results on Thursday, February 13, 2025

Jan 27, 2025, 5:00 PM EST - 1 year ago

Bio-Rad to Report Fourth Quarter and Full Year 2024 Financial Results on Thursday, February 13, 2025

Geneoscopy Closes $105M in Series C Funding Round to Power Next-Generation of Gastrointestinal Diagnostic Tests

Jan 8, 2025, 8:15 AM EST - 1 year ago

Geneoscopy Closes $105M in Series C Funding Round to Power Next-Generation of Gastrointestinal Diagnostic Tests

LH

Bio-Rad's Management to Host Investor Meetings at J.P. Morgan's 43rd Annual Healthcare Conference

Jan 2, 2025, 4:30 PM EST - 1 year ago

Bio-Rad's Management to Host Investor Meetings at J.P. Morgan's 43rd Annual Healthcare Conference

Bio-Rad's Management to Host Investor Meetings at Citi's 2024 Global Healthcare Conference

Nov 21, 2024, 9:00 AM EST - 1 year ago

Bio-Rad's Management to Host Investor Meetings at Citi's 2024 Global Healthcare Conference

Bio-Rad's Management to Participate in Fireside Chat During UBS Global Healthcare Conference

Oct 31, 2024, 9:00 AM EDT - 1 year ago

Bio-Rad's Management to Participate in Fireside Chat During UBS Global Healthcare Conference

Bio-Rad Laboratories, Inc. (BIO) Q3 2024 Earnings Call Transcript

Oct 30, 2024, 8:22 PM EDT - 1 year ago

Bio-Rad Laboratories, Inc. (BIO) Q3 2024 Earnings Call Transcript

Bio-Rad Laboratories beats quarterly profit estimates on strong sales in diagnostics unit

Oct 30, 2024, 6:09 PM EDT - 1 year ago

Bio-Rad Laboratories beats quarterly profit estimates on strong sales in diagnostics unit

Bio-Rad Reports Third-Quarter 2024 Financial Results

Oct 30, 2024, 4:15 PM EDT - 1 year ago

Bio-Rad Reports Third-Quarter 2024 Financial Results

Bio-Rad to Report Third Quarter 2024 Financial Results on Wednesday, October 30, 2024

Oct 14, 2024, 5:30 PM EDT - 1 year ago

Bio-Rad to Report Third Quarter 2024 Financial Results on Wednesday, October 30, 2024

Palantir Technologies, Dell Technologies, and Erie Indemnity Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600

Sep 6, 2024, 6:43 PM EDT - 1 year ago

Palantir Technologies, Dell Technologies, and Erie Indemnity Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600

ADNT CHCT CMP CNH DBI DDD DELL

Bio-Rad's Management to Participate in Fireside Chat During Wells Fargo's 2024 Healthcare Conference

Aug 22, 2024, 4:30 PM EDT - 1 year ago

Bio-Rad's Management to Participate in Fireside Chat During Wells Fargo's 2024 Healthcare Conference

Bio-Rad Appoints Jon DiVincenzo President, Chief Operating Officer

Aug 20, 2024, 8:30 AM EDT - 1 year ago

Bio-Rad Appoints Jon DiVincenzo President, Chief Operating Officer

Bio-Rad Laboratories, Inc. (BIO) Q2 2024 Earnings Call Transcript

Aug 1, 2024, 10:47 PM EDT - 1 year ago

Bio-Rad Laboratories, Inc. (BIO) Q2 2024 Earnings Call Transcript

Bio-Rad Labs cuts annual revenue forecast on weak demand for diagnostics products

Aug 1, 2024, 5:56 PM EDT - 1 year ago

Bio-Rad Labs cuts annual revenue forecast on weak demand for diagnostics products

Bio-Rad Reports Second-Quarter 2024 Financial Results

Aug 1, 2024, 4:15 PM EDT - 1 year ago

Bio-Rad Reports Second-Quarter 2024 Financial Results

Bio-Rad to Report Second Quarter Financial Results on Thursday, August 1, 2024

Jul 17, 2024, 4:30 PM EDT - 1 year ago

Bio-Rad to Report Second Quarter Financial Results on Thursday, August 1, 2024

Bio-Rad Names Anette Engelhardt Executive Vice President and President of Clinical Diagnostics Group

May 30, 2024, 9:00 AM EDT - 1 year ago

Bio-Rad Names Anette Engelhardt Executive Vice President and President of Clinical Diagnostics Group

Bio-Rad's Management to Participate in Fireside Chat During Jefferies Global Healthcare Conference

May 23, 2024, 4:15 PM EDT - 1 year ago

Bio-Rad's Management to Participate in Fireside Chat During Jefferies Global Healthcare Conference

Bio-Rad Laboratories, Inc. (BIO) Q1 2024 Earnings Call Transcript

May 7, 2024, 11:16 PM EDT - 1 year ago

Bio-Rad Laboratories, Inc. (BIO) Q1 2024 Earnings Call Transcript

Bio-Rad Laboratories reiterates 2024 revenue growth outlook; shares slip

May 7, 2024, 6:11 PM EDT - 1 year ago

Bio-Rad Laboratories reiterates 2024 revenue growth outlook; shares slip

SuperGreenToday
SuperGreenToday Feb. 23 at 2:58 PM
$BIO Share Price: $268.70 Contract Selected: Sep 18, 2026 $270 Calls Buy Zone: $21.42 – $26.46 Target Zone: $35.96 – $43.96 Potential Upside: 59% ROI Time to Expiration: 206 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
TheDizPlinTrader
TheDizPlinTrader Feb. 20 at 1:56 PM
$BIO 🧪 1 Hour Levels Price: $272.00 Support: $264.40 Resistance: $279.90 👉 Tap follow to keep these 1-hour levels on your feed.
0 · Reply
MarketMicrostructure
MarketMicrostructure Feb. 20 at 1:18 PM
$BIO Bio-Rad supplies life science and diagnostics tools. Growth depends on research funding. Margins benefit from consumables.
0 · Reply
ZacksResearch
ZacksResearch Feb. 19 at 2:15 PM
$BIO just reminded the market that margins matter. ⚠️ Q4 EPS missed estimates, margins shrank, and shares slid 12% — even with revenue growth and a rebound in Clinical Diagnostics sales. Top-line strength wasn’t enough to offset profitability pressure. Is this a warning sign or an overreaction? Get the full picture 👉 https://www.zacks.com/stock/news/2871875/bio-rads-q4-earnings-miss-estimates-revenues-surpass-stock-down?cid=sm-stocktwits-2-2871875-teaser-34197&ADID=SYND_STOCKTWITS_TWEET_2_2871875_TEASER_34197
0 · Reply
ZacksResearch
ZacksResearch Feb. 19 at 1:15 PM
$BIO drops 12.3% after Q4 earnings miss! 📉 EPS of $2.51 fell short by 2.3%, and operating margins missed expectations, causing investor concern. ⚠️ See the full breakdown here 👉 https://www.zacks.com/stock/news/2871875/bio-rads-q4-earnings-miss-estimates-revenues-surpass-stock-down?cid=sm-stocktwits-2-2871875-body-34160&ADID=SYND_STOCKTWITS_TWEET_2_2871875_BODY_34160
0 · Reply
Bazzzigar
Bazzzigar Feb. 17 at 1:02 PM
$BIO UNH
0 · Reply
SuperGreenToday
SuperGreenToday Feb. 13 at 10:20 PM
$BIO Share Price: $256.26 Contract Selected: Sep 18, 2026 $300 Calls Buy Zone: $11.05 – $13.65 Target Zone: $19.04 – $23.28 Potential Upside: 63% ROI Time to Expiration: 216 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
StocktwitsEarnings
StocktwitsEarnings Feb. 12 at 9:24 PM
$BIO Q4 '25 Earnings Results & Recap • Reported GAAP EPS of $26.69 up 204.38% YoY • Reported revenue of $693.2M up 3.85% YoY • Bio-Rad expects non-GAAP currency neutral revenue growth of approximately 0.5% to 1.5% and an estimated non-GAAP operating margin of 12.0% to 12.5% for the full-year 2026.
0 · Reply
stock_head
stock_head Feb. 12 at 8:15 PM
$BIO someone is slamming a bunch of otm calls on this rn. Looks like they might have ER today
1 · Reply
HHill
HHill Feb. 12 at 8:06 PM
$BIO loading calls here Will rocket 🚀
0 · Reply
SuperGreenToday
SuperGreenToday Feb. 9 at 6:31 PM
$BIO Share Price: $292.07 Contract Selected: Sep 18, 2026 $300 Calls Buy Zone: $28.05 – $34.65 Target Zone: $49.43 – $60.42 Potential Upside: 66% ROI Time to Expiration: 220 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
EVBatteryCapital
EVBatteryCapital Feb. 4 at 11:53 AM
$BIO is a life sciences tools and services conglomerate; its clinical research and bioprocessing segments are facing headwinds from constrained biotech funding.
0 · Reply
JackDarwin
JackDarwin Jan. 27 at 10:24 AM
$BIO Bullish Tweezer + Bullish Piercing Candlestick Pattern
0 · Reply
StockIt21
StockIt21 Jan. 23 at 5:00 PM
$BTC.X $AXS $SKR.X Seeker Solana Snartphone Token $ELSA.X New on Coinbase $BIO $FUN1.X (Sport. Fun) Prediction Market Sports, Fantasy, NFL Super Bowl Incoming & FIFA High Watch Alert ⚠️ 📢 TOP MOMENTUM & TRENDING GAINERS!!! Bitcoin moving on Gold/Silver All-Time Highs Total Crypto Market Rebounding!!! Follow the Trends: A.I., Technology, ZKP, Science Tech, Predictions Markets (Sports, Politics, Etc), DeFi/De-Sci Know Who You Follow Know What You Own
0 · Reply
BillionerOfKing
BillionerOfKing Jan. 16 at 5:21 PM
$BIO Current Stock Price: $317.42 Contracts to trade: $320 BIO Jan 16 2026 Call Entry: $2.70 Exit: $5.23 ROI: 94% Hold ~27 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Dec. 25 at 1:53 PM
$BIO RSI: 29.02, MACD: -3.5929 Vol: 8.88, MA20: 311.20, MA50: 314.84 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
RocketshipCalls
RocketshipCalls Dec. 10 at 3:14 PM
$SAVA 🧲 The current setup (why people are watching again) You now have: • CEO buying (confidence ✅) • Compressed price (optionality ✅) • Historical squeeze behavior (volatility ✅) • One of the largest unmet medical needs in history (Alzheimer’s ✅) That’s why SAVA doesn’t die — it reloads. $SPY $BIO $SRPT Get ready for a squeeze soon! One good catalyst and we squeeze! Huge short cover incoming!
1 · Reply
BillionerOfKing
BillionerOfKing Dec. 4 at 6:53 PM
$BIO Current Stock Price: $318.34 Contracts to trade: $320 BIO Dec 19 2025 Call Entry: $3.00 Exit: $5.75 ROI: 92% Hold ~30 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
SuperGreenToday
SuperGreenToday Nov. 13 at 3:21 PM
$BIO Share Price: $325.39 Contract Selected: Jun 18, 2026 $370 Calls Buy Zone: $12.75 – $15.75 Target Zone: $20.46 – $25.00 Potential Upside: 52% ROI Time to Expiration: 216 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
SuperGreenToday
SuperGreenToday Nov. 5 at 3:09 AM
$BIO Share Price: $311.51 Contract Selected: Jun 18, 2026 $370 Calls Buy Zone: $8.50 – $10.50 Target Zone: $15.04 – $18.38 Potential Upside: 67% ROI Time to Expiration: 225 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply